Rhodiola grows in cold regions and at high altitudes in Europe and Asia, where its roots have traditionally been used to increase resistance to physical stress.
While there are more than 200 species of rhodiola, Rhodiola rosea is considered preferable, because it contains rosavins. Supplements generally contain a minimum of 3% rosavins.
Rhodiola is considered an adaptogen, which is an agent that is believed to normalize functioning and stimulate healing of cells. It has been used to prevent fatigue and enhance physical and mental performance. Rhodiola may also provide benefit in bladder cancer, lung disease, and exercise and mental performance, but more studies are needed to confirm these findings.
Uses | Grade* |
Adaptogen Rhodiola is considered an adaptogen. Adaptogens reportedly regulate stress resistance and increase performance, energy, and endurance. Initial results for use of rhodiola as an adaptogen are promising, but further research is required before conclusions can be made. | C |
Anxiety Rhodiola is popularly used for anxiety and other mood-related disorders. In human research, rhodiola was found to reduce cortisol, a hormone whose levels increase during stress. Based on preliminary research, rhodiola may be beneficial in reducing anxiety; however, large, well-designed clinical trials are needed before a conclusion can be made. | C |
Bladder cancer Preliminary research suggests that rhodiola may benefit patients with bladder cancer. Well-designed studies are needed before a conclusion can be made. | C |
Depression Rhodiola has been used traditionally to reduce depression. In preliminary study of patients with mild-to-moderate depression, the SHR-5 standardized extract of rhodiola decreased symptoms of depression. Further research is needed before conclusions can be made. | C |
Exercise performance enhancement Limited study of rhodiola for exercise performance enhancement is promising; however, additional studies are needed before a conclusion can be made. | C |
Fatigue Rhodiola has been used to increase energy and reduce fatigue. More well-designed studies are required. | C |
Hypoxia (lack of oxygen) Rhodiola has been hypothesized to protect against injury caused by too little oxygen. Review of human research indicates that rhodiola may improve oxygenation. More high quality research is needed. | C |
Lung disease (acute injury) Early study suggests that rhodiola may protect the lungs from acute injury. Further studies are needed before a firm conclusion may be made. | C |
Mental performance (during fatigue) Early study suggests that rhodiola may benefit learning, memory, and mental performance. Well-designed studies are needed before a conclusion may be made. | C |
Tuberculosis Preliminary study suggests that the combination product Dzherelo (containing rhodiola) may benefit patients with tuberculosis. Additional research evaluating rhodiola alone is needed before a conclusion can be made. | C |
*Key to grades:
A: Strong scientific evidence for this use;
B: Good scientific evidence for this use;
C: Unclear scientific evidence for this use;
D: Fair scientific evidence against this use (it may not work);
F: Strong scientific evidence against this use (it likely does not work).
Although various doses have been studied, there is no proven safe or effective dose for rhodiola. Typically, 100 to 600 milligrams of rhodiola has been used. High doses are considered to be 1,000 milligrams or more daily. Some sources suggest that rhodiola should be taken on an empty stomach and should not be used continuously.
As an adaptogen, 100-300 milligrams of rhodiola (standardized to 1% salidroside and/or 40-50% phenylpropanoids) has been taken by mouth three times daily.
For anxiety, 170 milligrams of rhodiola (Rhodax®; Phoenix Laboratories by Bodyonics Ltd.) has been taken by mouth twice daily for 10 weeks.
For bladder cancer, rhodiola extract of unknown dose has been taken by mouth for unknown duration.
For depression, 100-1,000 milligrams of rhodiola (standardized to 3% rosavins and 1% salidrosides) has been taken by mouth daily in 2-3 doses on an empty stomach. A dose of 340 milligrams daily (two tablets of SHR-5 once daily) and 680 milligrams (two tablets of SHR-5 twice daily) have been taken by mouth.
For exercise performance enhancement, the following doses have been taken by mouth: 50 milligrams of rhodiola extract (SHR-5) twice daily for 20 days; 100 milligrams of rhodiola (Rhodiolin, CaliVita International, United States), each capsule containing 100 milligrams of rhodiola concentrate and 5.0 milligrams of zinc, twice daily for four weeks; 200 milligrams of rhodiola extract, standardized to 3% rosavin and 1% salidroside, as an acute dose or once daily for four weeks; 3 milligrams per kilogram of body weight of rhodiola as an acute dose before exercise; and 340 milligrams of Rhodax® (Phoenix Lab; containing 30 milligrams of rhodiola) twice daily (morning and evening) for 30 days.
For fatigue, 144-576 milligrams of rhodiola (SHR-5 extract) has been taken by mouth daily for up to 28 days.
For hypoxia, rhodiola (dose unavailable) has been taken by mouth for seven days and for 24 days.
For lung disease (acute injury), 4 grams of rhodiola has been taken by mouth daily for 7-10 days before surgery and 5-7 days after surgery in patients with severe pulmonary hypertension undergoing cardiopulmonary bypass.
For mental performance during fatigue, the following doses have been taken by mouth: 100-1,000 milligrams of rhodiola (standardized to 3% rosavins and 1% salidrosides) daily in 2-3 doses on an empty stomach; 170 milligrams of rhodiola extract (SHR-5) daily for two weeks; an acute dose of 3 milligrams per kilogram body weight of rhodiola before exercise; 100-555 milligrams of rhodiola extract (SHR-5) daily for up to 20 days.
There is no proven safe or effective dose for rhodiola in children.
For lung disease (acute injury), 2 grams of rhodiola has been taken by mouth daily for 7-10 days before surgery and 5-7 days after surgery in patients with severe pulmonary hypertension undergoing cardiopulmonary bypass.